Autoimmune Diseases  >>  otelixizumab (ChAglyCD3)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
otelixizumab (ChAglyCD3) / GSK
NCT00451321: TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

Terminated
2
88
US, Canada
Otelixizumab
GlaxoSmithKline, Juvenile Diabetes Research Foundation
Diabetes Mellitus, Type 1
12/11
12/11

Download Options